Serene Lee

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.

Journal: Pharmacopsychiatry

Published: February 05, 2026

The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review.

The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review.

Journal: Psychiatry research

Published: November 19, 2025

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.

Journal: CNS spectrums

Published: June 09, 2025

Effects of glutamatergic modulators on striatal activation, functional connectivity and reward in persons with major depressive disorder and healthy controls: A systematic review of fMRI studies.

Effects of glutamatergic modulators on striatal activation, functional connectivity and reward in persons with major depressive disorder and healthy controls: A systematic review of fMRI studies.

Journal: Journal of affective disorders

Published: May 06, 2025

The sigma-1 receptor: a mechanistically-informed therapeutic target for antidepressants.

The sigma-1 receptor: a mechanistically-informed therapeutic target for antidepressants.

Journal: Expert opinion on therapeutic targets

Published: April 29, 2025

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.

Journal: Therapeutic advances in psychopharmacology

Published: March 30, 2025

A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain - CORRIGENDUM.

A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain - CORRIGENDUM.

Journal: CNS spectrums

Published: December 10, 2024

A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.

A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.

Journal: CNS spectrums

Published: November 25, 2024

The Efficacy of Pharmacological Interventions in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: A Systematic Review.

The Efficacy of Pharmacological Interventions in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: A Systematic Review.

Journal: Bipolar disorders

Published: September 25, 2024

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.

Journal: Annals of general psychiatry

Published: August 09, 2024

Showing 1-10 of 10

Last Updated: 09/26/2026